The objective of this study was to systematically develop with Quality by Design (QbD) approach of Effervescent Floating Multiple unit Minitablets (EFMM) of metoprolol succinate (MS) for once-a-day dosing using hydrophobic grade of gelucire in order to increase gastric residence time. Methods: Risk assessment using Failure Mode Effect Analysis (FMEA) was conducted and further screened using taguchi design. A Box-Behnken Design (BBD) was adopted for the process of optimization. The dissolution profile of optimised formulation was compared with the marketed formulation. Drug compatibility study and stability study were also conducted. Results: After conducting risk assessment and screening amount of gelucire 43/01(G 43/01), HPMC K15 M (HM) and NaHCO 3 (SB) were found to be as significant factor. The process of optimisation results the single dose of EFMM MS consisting of 125 mg of G 43/01, 72 mg of HM and 28 mg of SB which shows an average of Floating Lag Time (FLT) within 3 min, Floating Time (FT) of 19 hr 36 min, time to release 50% of drug (t50) of 6 hr 38 min and time to release 90% of drug (t90) of 19 hr 12 min. The optimised formulation found to have better dissolution profile as compared to the marketed formulation. The stability study revealed no significant change in various parameters before and after storage. Conclusion: It can be concluded that an optimum combination of various excipient can be used to increase the gastric residence time, sustaining the drug release and ultimately achieve the desired objective of once-a-day dosing of MS.
INTRODUCTION
Since a long time, oral Controlled Release (CR) formulations are popularly applied as drug reservoirs for controlling the release of drugs over a defined period of time, 1 Gastric Retention Time (GRT) in transit of the dosage forms has the major importance for drugs which are having site of absorption in different part of Gastro Intestinal Tract (GIT). 2 Short transit time of drug with absorption window in stomach causes release of drug in non-absorbing distal segment of GIT leading to poor bioavailability. These aspects lead to the development gastro retentive drug delivery systems. 3 GRDDS have been categorised into different system like bio-adhesive systems, floating systems, expandable systems and high-density systems. 4 One of the most suitable approaches is the designing of Floating Drug Delivery System (FDDS) using different rate controlling polymer and gas generating agent. 5 Vacuum, air or an inert gas can be incorporated in a floating chamber made up of polymer for formulation of floating drug delivery system. 6, 7 Dose-dumping is the main disadvantage associated with sustained-release single-unit dosage form due to polymer failure. 8 Like other multiple unit systems, minitablets can be considered as promising approach which releases the drug from the subunits (minitablets) after disintegration of capsule. 9 The drug having short biological half-life favours development of a Sustained Release (SR) while drug with absorption window in upper GI tract favours for development of floating drug delivery system, respectively. 10 Metoprolol Succinate (MS), a β-selective adrenergic blocking agent used to treat patients with hypertension or angina pectoris. 11 Considering the fact of MS having short half-life (3-4 hr) favours for development of a Sustained Release (SR) while absorption window in upper GI tract favours for development of floating drug delivery system. 12, 13 Single dose per day is essential to reduce dosage frequency, facilitates patient compliance and decrease the risk of myocardial infarction. 14, 15 It has been reported that MS absorption window mainly at duodenum and jejunum and also exhibits a high solubility at gastric pH. 16 These characteristics of MS suggest its high suitability for gastro retentive multiple unit drug delivery system. Hydrophobic polymer can be used in the preparation of sustained and floating formulations. Extreme hydrophobicity (HLB 1) of Gelucire 43/01 is the reason for its release retarding ability. 17 Due to its low melting point (43°C), it can be used for the preparation of sustained released formulations by melt granulation method. Patel et al. have reported that only gelucire 43/01 based granules could not achieve the desired sustainability and to sustain the release further release rate modifiers were used. 18 Jamula et al. reported that the drug release of gelucire 43/01 based granules was sustained by compressing into minitablets. 19 Thakkar et al. have reported that to achieve desirable floating for any gelucire based formulation incorporation of swell able polymer and gas generating agent is essential. 20 Higher concentration of gelucire 43/01 content promote better controlling of the drug release because of the increase of lipid matrix density and large diffusion path length. 21 Hence in the present research work, it is planned to use hydrophobic polymer like gelucire 43/01, release modulator like HPMC K15M, gas generating agent like NaHCO 3 in the formulation of Effervescent Floating Multiple unit Minitablets (EFMM) of Metoprolol Succinate (MS). Quality by Design (QbD) approach is adopted by different researcher for the development floating DDS. Joseph M. Juran was first researcher who published the concept of QbD. 22 Quality by Design (QbD) is defined a systematic approach that starts with some justified objectives, identifying the process parameter with its control, quality risk management, screening of significant factor and its optimisation. 23, 24 QbD methodology includes defining the Quality Target Product Profile (QTPP), Critical Quality Attributes (CQAs), risk assessment, screening of significant factor, data analysis using Design of Experiments (DoE) and optimisation using Response Surface Methodology (RSM) to plot the design space. 25, 26 The QTPP is a prospective summary of the quality characteristics of a drug product in order to achieve the objective of formulation design of EFMM. The first step in the risk assessment is to identify all possible risk factors which could influence the CQAs of EFMM using the Ishikawa fish-bone diagram. 27 The next step is risk analysis to screen the influential factor. FMEA is a progressive and systematic approach in order to identify the various potential failure mode associated with the product or process design. 28 Design of Experiments (DOE) is a statistical technique which can be used for optimisation of any formulation with the regression analysis methods. 29, 30 In recent year many researcher apply quality by design as tool in order to optimise and develop sustained release gastro-retentive dosage form. Chudiwala et al. developed sustained release gastro-retentive tablet formulation of nicardipine hydrochloride applying Quality by Design (QbD) approach. He found that the release of drug from the formulation effected by the concentration of variable such as glyceryl behenate (mg/tab) and HPMC K15M (mg/tab) whereas floating lag time influence by the concentration of sodium bicarbonate (mg/tab). 31 Rapoul K. et al. 2013 prepared effervescent floating tablets of metronidazole by applying the Box-Behnken design in order to prolong gastric residence time and improve local effect in stomach in the treatment of peptic ulcer. 32 On the basis of these literatures, the present research for the development and characterization of effervescent floating multiple unit minitablets of metoprolol succinate is performed using Quality by Design approach.
MATERIALS AND METHODS
Metoprolol succinate was received as a gift sample from Aurobindo Pharma (Hyderabad, India). Neusilin US2 was kindly provided as ex-gratis by Gangwal Chemicals Pvt Ltd (Mumbai, India). Gelucire 43/01 was provided as a gift sample from Gattefosse Pvt Ltd (Mumbai, India). All other chemicals and solvent were of analytical grade or highest quality and were used as such as obtained. This article does not contain any studies with human or animal subjects performed by any of the authors.
Methods

Identification and justification of various QTPP and CQAs
The QTPP of the EFMM was identified as an inevitable abstract of desired quality characteristics for the product element of a QbD approach. The QTPP elements were set-up considering the need of sustaining drug release, increasing the gastric retention time and reducing the dosage frequency. CQAs were identified with proper justification to achieve the formulation objective for the development of EFMM once-a-day dosing formulation. 33
Risk assessment
At first risk factors were identified which could influence the CQAs of EFMM using the Ishikawa fish-bone diagram. Then risk analysis was carried out using FMEA to screen the influential factor. The Failure Mode Effect Analysis (FMEA) method was used as tool in order to conduct the risk analysis. Each factor was assigned a score in terms of Severity (S), Detectability (D) and Occurrence (O). S, D and O scores were multiplied together which gave the "Risk Priority Number" (RPN) for each of the risk factor. We assigned S, D and O of 10 for high risk case, 1 for least risk case and 5 for moderate risk case. 34, 35 
Screening of factors using Taguchi design
Screening of factors was carried out employing a 7-factor 2-level Taguchi design in order to identify the influential factor affecting the CQAs. According to the design matrix a series of formulations were prepared by melt granulation method and characterised for the CQAs as described below. For each CQA regression equation were analysed to study the effect of each factor. Pareto charts and half normal were plotted to illustrate the influence of each factor on the CQAs. Significance of each factor was analysed using ANOVA as tool. On the basis of P value the significant variable were identified. 36, 37 
Preparation of EFMM of MS
Melt granulation technique was adopted for preparing the solid dispersion of MS and gelucire 43/01. Gelucire 43/01 was heated on a water bath in a temperature range of 50-60°C with continuous stirring. To the molten liquid of gelucire 43/01, MS powder was added and stirred for 10 min. The preheated (80°C) neusilin US2 was added to the dispersion with continued mixing for 10 min in order to solidify the molten mass. The required amount of HPMC K15M, MCC and NaHCO 3 was added to the mixture and sieved through mesh no. # 40 to get uniform size granules. The resultant granules were compressed into 3 mm circular minitablets each containing 2.5 mg of MS. Twenty minitablets were filled into a gelatine capsule of size '0'.
Measurement of FLT
The floating lag time was determined by conducting vitro buoyancy studies for each of the formulation. Each of the EFMM was placed in a beaker containing 100 mL of 0.1N HCl. Floating Lag Time (FLT) may be defined as the time required for each of the minitablet to start floating on the surface of the dissolution media.
Measurement of FT
EFMM tablets were placed in USP dissolution apparatus-II containing 900mL of 0.1N to determine FT of each formulation. FT is the total time of floating when a dosage form is placed in a dissolution media.
In vitro dissolution studies (Measurement of t50 and t90)
In vitro dissolution studies of different EFMM were conducted in a USP dissolution apparatus-II taking 0.1 N HCl as dissolution medium. 5mL sample was withdrawn at regular time intervals up to 24 hr (1, 2, 4, 6, 8, 12, 16, 20 and 24 hr) and were analysed using UV-spectrophotometer at 270 nm. The time taken to release 50% of drug (t50) and time taken to release 90% of drug (t90) were determined during the dissolution test.
Experimental design, optimisation and analysis
Systematic optimization of EFMM of MS was accomplished employing Box-behnken Design (BBD) with the help of design expert ver. 11.1.01 software (Stat-Ease, Minneapolis, MN). The highly influential factor finalised after screening and risk assessment studies were correlated with the Critical Quality Attributes (CQAs). According to the design matrix a series of formulations were prepared by melt granulation method and characterised for the CQAs as described above. For each CQA regression equation were analysed and by using response surface analysis contour plot and 3D plot were plotted. Optimisation of EFMM of MS were carried out by setting up the upper and lower limit of different CQAs. The overlay plot was constructed to identify the design space. 38, 39 
Comparison of drug release kinetics
The drug release pattern of the optimized EFMM, marketed conventional tablet and marketed Sustain Release (SR) tablet were compared. The in vitro dissolution study was conducted as prescribed above using a USP dissolution apparatus-II.
Compatibility studies using Differential Scanning Calorimeter (DSC)
The pure MS, physical mixture and optimised EFMM were examined for compatibility study employing DSC (Shimazu Ltd., Japan). The heat capacity of MS, physical mixture and optimised EFMM was analysed and DSC curve was plotted over a temperature rang in order to predict the thermodynamic compatibility.
Accelerated stability study
Accelerated stability study of the optimised EFMM of MS was conducted for a period of 6 months as prescribed in ICH guidelines. The formulations were examined at the time points of 0, 3 and 6 months for the different CQAs. ANOVA study was conducted in order to find any significant differences within the response obtained at different time point.
RESULTS AND DISCUSSION
Identification and justification of various QTPP and CQAs
On the basis of the objective to prepare sustain release gastro retentive system various QTPP elements such as dosage form, dosage type, dosage strength, route of administration, drug release profile and stability were set-up. The quality characteristics of the Effervescent Floating Multiple unit Minitablets (EFMM) of Metoprolol Sccinate (MS) along with justification have been discussed in Table 1 . Various Qualities Attribute (QAs) such as physical attributes, the times required for 50% of the cumulative drug release(t50), the times required for 90 % the cumulative drug release (t90), Floating Leg Time (FLT), Floating Time (FT), bouncy percentage, drug content. The justifications for selection of CQAs affecting the EFMM of MS were depicted in Table 2 . The times required for 50% of the cumulative drug release (t50), Since all the minitablets in one capsule are expected to float with less variability hence considered as noncritical the times required for 90% the cumulative drug release (t90), floating leg time and floating time were identified as the potential CQAs.
Risk assessment
Fish-bone diagram of different factor affecting CQAs of MS EFMM formulation was constructed for the identification of potential risk factors (failure modes) on the basis of literature and previous research experiences. Figure 1 portrays the resultant fish-bone diagram depicting the effect of man, material, measurement, process, equipment, environment on CQAs for the development of EFMM of MS. Based on the risk identification the risk analysis was carried out by assigning ordinal scores to each factor in terms of Severity (S), Detectability (D) and Occurrence (O) using FMEA tool. respectively. These factors were further screened using teguchi design and other factors with a lower RPN were eliminated from further study.
Screening of factors using Taguchi design
Taguchi design was employed to screen factors shortlisted using FMEA analysis. Table 4 represents the The influence of each factor on various CQAs was represented in terms of half-normal plots and Pareto charts as depicted in Figure 2 . (C-SB) were found to be above the t-value limit and/ or Bonferroni's limits for all the CQAs hence considered as significant. Table 5 represents the summary of ANOVA for the factor screening and its significance as per teguchi design. The P values of the regression coefficients were determined to evaluate the significance of each factor on each of the response. The model factor such as amount of gelucire 43/01(A-G 43/01), amount of HPMC K15 M (B-HM) and amount of NaHCO 3 (C-SB) are significant science the Pvalue is less than standard α value (i.e. 0.05) and other factor having P values greater than 0.1000 indicate the model terms are not significant. Thus, from the factor screening study the factors amount of Gelucire 43/01(A-G 43/01), amount of HPMC K15 M (B-HM) and amount of NaHCO 3 (C-SB) were finally selected for further optimization. .00BC+22.13A²-+27.88C²
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Response surface analysis of contour plot and 3D plot
Response surface analysis of contour plot and 3D plot was carried out to evaluate the interaction effect of gelucire 43/01(A-G 43/01), amount of HPMC K15 M (B-HM) and amount of NaHCO 3 (C-SB). Figure 3 represents the contour plot and 3D plot of the various CQAs by observing the plot it can be predicted that at low level of B-HM also the prevalence of blue region i.e. low FLT was high only when the concentration of C-SB was on higher side. A comparative study among these formulations showed run no 12 have the minimum value of FLT i.e. 122 sec while run no 5 have maximum FLT value i.e. 368 sec. In case of FT, it was observed that at high level of both A-G 43/01 and B-HM the prevalence of red region i.e. high value of FT achieved while C-SB has negative influence on this CQA. The value of FT found to be in the range of 837 min (run 8) to 1272 min (run 9). Contour plot and 3D plot indicating that the value of t50 and t90 gradually increases with increment in A-G 43/01 and B-HM and reverse with increment in C-SB. The results showed that an increase amount of SB did not affect much to FLT but decrease the t50 and t90. Both G 43/01 and HM has significant role for increasing value of t50 and t90. Figure 4 illustrates the normal plot of residual and linear correlation plots between the predicted and observed responses for different CQAs. It can be predicted from the graph that there is a high level of correlation between actual and predicted value. The residual plot indicates high level of significance of BBD approach. Table 8 represents the summary of the BBD quadratic model in the process of optimization of the EFMM. 
ANOVA of the experimental design
Summary of BBD quadratic model
Optimisation of EFMM of MS and construction of overlay plot to identify the design space
For obtimistion the desirable goal was fixed for variour responses. On the basis of the QTPP requirement the range of various CQAs were fixed with appropriate weightage which were then processed for optimisation. The summary of the optimisation process along with predicted and experimental value of responses of the optimised formulation are expressed in Table 9 .
The optimised single dose of EFMM of MS consisting of 125 mg of G 43/01, 72 mg of HM, 28 mg of SB, 125 mg of N US2, 100 mg of MCC and 50 mg of MS which showed an average of FLT within 3 min, FT of 19 hr 36 min, t50 of 6 hr 38 min and t90 of 19 hr 12min. The said optimized run exhibited process of controlled release and gastro retentive for one day and was found to be dependent on a particular pair and ratio of G 43/01, HM and SB. Figure 5 portray the overlay plot with design space and also depicts the selected optimised EFMM composition.
Comparison of drug release kinetics
The drug release pattern of the optimized EFMM, marketed conventional tablet and marketed Sustain Release (SR) tablet is illustrated in Figure 6 . The optimised EFMM MS showed better dissolution profile than both the marketed formulation. The drug release pattern of the marketed conventional tablet showed more than 96% drug release within 4 h while in case of marketed Sustain Release (SR) tablet more than 30% of drug released at initial 1h only. Hence an optimum combination of gelucire 43/01 and HPMC K 15M provide a better controlled release pattern then the marketed formulation. Applying different kinetic model such as zero-order, first-order and Higuchi model the correlation coefficient (r 2 ) were calculated. The correlation coefficient (r 2 ) were found to be 0.979, 0.611 and 0.987 for zero-order in case of optimized EFMM, marketed conventional tablet and marketed Sustain Release (SR) Figure 7 depicts the DSC curve of pure MS, physical mixture and optimised EFMM. The resultant peak is at 137.1°C, 137.8°C and 134.8°C for pure MS, physical mixture and optimised EFMM respectively. It confirms no significant overlapping or shifting of peak in the thermo-gram. These results ratified absence of any physiochemical incompatibility between the drug and polymer.
Accelerated stability studies
The optimised EFMM of MS was examined for 6 months of accelerated stability study as prescribed in method section. The CQAs of the optimised EFMM at various intervals were subjected to ANOVA for determining any significant difference. The P value and F value of the ANOVA during accelerated stability study is shown in Table 10 . These values indicate there is no significant difference of the CQAs during the study period. Hence it can be concluded that the optimised EFMM found to satisfy the stability criteria.
CONCLUSION
In this present research work a systematic development of EFMM MS was carried out using QbD approach which result an optimised formulation with desired CQAs. Risk assessment study using FMEA was conducted which identify gelucire 43/01(G 43/01), amount of HPMC K15 M (HM), amount of NaHCO 3 (SB), amount of Neusilin US2 (N US2), Compression Force (CF), Stirring Time (ST) and Melting Temperature (MT) as significant factor. Taguchi design was used in order to select the potential factor correspond to the CQAs. After screening 8 run at two level amount of gelucire 43/01(G 43/01), amount of HPMC K15 M (HM) and amount of NaHCO 3 (SB) were found to be the influential factors which were further optimised using BBD. The optimised single dose of EFMM of MS consisting of 125mg of G 43/01, 72mg of HM, 28mg of SB, 125mg of N US2, 100mg of MCC and 50 mg of MS which showed an average of FLT within 3 min, FT of 19 hr 36 min, t50 of 6 hr 38 min and t90 of 19 hr 12 min. After experimental study it was confirmed that the said optimized EFMM exhibited process of controlled release and gastro retentive for one day with effective FLT. The optimised formulation found to have better dissolution profile as compared to the marketed formulation. DSC study justifies no interaction of drug with various excipients. Accelerated stability study of the optimised EFMM MS confirms insignificant changes in the CQAs during storage which was evident by conducting ANOVA. The present research concluded that an optimum amount of Gelucire 43/01, HPMC K15M and NaHCO 3 in the formulation of EFMM of MS is effective to achieve desired drug release rate and gastric residence time.
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SUMMARY
In this present research work a systematic development of EFMM MS was carried out using QbD approach which result an optimised formulation with desired CQAs. Taguchi design was used in order to select the potential factor correspond to the CQAs. After screening 8 run at two level amount of gelucire 43/01(G 43/01), amount of HPMC K15 M (HM) and amount of NaHCO 3 (SB) were found to be the influential factors which were further optimised using BBD. After experimental study it was confirmed that the said optimized EFMM exhibited process of controlled release and gastro retentive for one day with effective FLT. The optimised formulation found to have better dissolution profile as compared to the marketed formulation. The present research concluded that an optimum amount of Gelucire 43/01, HPMC K15M and NaHCO 3 in the formulation of EFMM of MS is effective to achieve desired drug release rate and gastric residence time.
